TapewireFind a company

person · Reporting owner

Powers Linda F

Disclosed activity across 2 companies

Tapewire entity
145922
SEC CIK
0001289624

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Inmune Bio, Inc.INMB · Entity 709410% ownerJanuary 27, 2020January 29, 2020
NORTHWEST BIOTHERAPEUTICS INCNWBO · Entity 5982Director · President and CEO · 10% ownerOctober 14, 2020October 16, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Inmune Bio, Inc.

Report date January 27, 2020 · Filed January 29, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect210,000 Reported balance After 2020-01-27 transaction · row 1
1 source row

Row 1 · 2020-01-27 · Sale · Disposed 220,000 · Balance 210,000

Common StockSEC Table I · non-derivativeIndirectHeld in the name of Toucan Capital.700,000 Reported balance Holding disclosure · report date 2020-01-27 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 700,000

F1: Shares held in name of Toucan Capital. Ms. Powers has voting and dispositive power over these shares.

Filing footnotes · ownership attribution and instrument terms

F1: Shares held in name of Toucan Capital. Ms. Powers has voting and dispositive power over these shares.

NORTHWEST BIOTHERAPEUTICS INC

Report date October 14, 2020 · Filed October 16, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Options to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2030-12-01Direct29,558,724 Reported balance After 2020-10-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2020-10-14 · Gift · Disposed 3,000,000 · Balance 29,558,724

F1: These options are gifts from Ms. Powers for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: These options are gifts from Ms. Powers for no consideration.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 14, 2020 Filed Oct 16, 2020 22:58 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 GiftOptions to purchase Common Stock · Derivative 3,000,000 $0.00 Strike: $0.25 $0.00
Disclosure

SEC source: 0001104659-20-115717 · tm2022243d17_4.xml · derivative · entry 1

Powers Linda F · CIK 0001289624 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,558,724

Underlying: Common Stock, par value $0.001 per share · 3,000,000 shares

Expires 2030-12-01

F1 · kind: These options are gifts from Ms. Powers for no consideration.

Read SEC document
July 02, 2020 Filed Jul 3, 2020 01:55 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 GrantOptions to purchase Common Stock, par value $0.001 · Derivative 8,665,524 $0.00 Strike: $0.21 $0.00
Disclosure

SEC source: 0001104659-20-080814 · tm2022243d14_4.xml · derivative · entry 2

Powers Linda F · CIK 0001289624 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,665,524

Underlying: Common Stock, par value $0.001 · 8,665,524 shares

Expires 2030-07-02

F2 · kind: These options were approved in January 2020. The exercise price was determined based upon the pricing in year-end financings with unrelated investors. However, these options have not been executed and implemented (granted) until now.

Read SEC document
July 02, 2020 Filed Jul 3, 2020 01:55 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 GrantOptions to purchase Common Stock, par value $0.001 · Derivative 2,104,905 $0.00 Strike: $0.25 $0.00
Disclosure

SEC source: 0001104659-20-080814 · tm2022243d14_4.xml · derivative · entry 1

Powers Linda F · CIK 0001289624 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,104,905

Underlying: Common Stock, par value $0.001 · 2,104,905 shares

Expires 2030-07-02

F1 · kind: These options were already approved and publicly reported in 2018. The exercise price was determined with reference to the pricing for unrelated investors at that time. However, the documents to implement and issue (grant) them have not been executed until now.

Read SEC document
July 02, 2020 Filed Jul 3, 2020 01:55 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 GrantOptions to purchase Common Stock, par value $0.001 · Derivative 32,558,724 $0.00 Strike: $0.25 $0.00
Disclosure

SEC source: 0001104659-20-080813 · tm2022243d13_4.xml · derivative · entry 1

Powers Linda F · CIK 0001289624 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,558,724

Underlying: Common Stock, par value $0.001 · 32,558,724 shares

Expires 2030-12-01

F1 · kind: These options were awarded in part for service during the last 2 years. However, the documents to implement and issue (grant) them have not been executed until now. The $0.25 exercise price was determined with reference to the pricing for unrelated investors at the time of approval, which was the trailing 10-day average closing market price of the Company's stock, which was about $0.22. These options are subject to certain vesting requirements. They are also suspended and will not become exercisable until December 1, 2020.

Read SEC document
July 02, 2020 Filed Jul 3, 2020 01:53 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 GrantWarrants to purchase Common Stock · Derivative 15,249,474 $0.00 Strike: $0.21 $0.00
Disclosure

SEC source: 0001104659-20-080806 · tm2023608d1_4.xml · derivative · entry 1

Powers Linda F · CIK 0001289624 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,249,474

Underlying: Common Stock, par value $0.001 per share · 15,249,474 shares

Expires 2025-11-01

F1 · kind: These warrants were in partial consideration of Ms. Powers' loans of $5.4 million to the Company and forbearance on the repayment of those loans. These warrants were approved and publicly reported in 2018. However, the documents to implement and issue (grant) these warrants were not executed until now. The exercise price was determined with reference to the price per share paid by unrelated investors.

Read SEC document
April 30, 2020 Filed May 2, 2020 01:12 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 OtherWarrants · Derivative 29,411,760 Not disclosed Strike: $0.22 Not disclosed
Disclosure

SEC source: 0001104659-20-055770 · tm2018427d1_4.xml · derivative · entry 2

Powers Linda F · CIK 0001289624 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,411,760

Underlying: Common Stock, par value $0.001 · 29,411,760 shares

Expires 2023-05-01

F3 · kind: J is the transaction code for "other acquisitions". It covers the deemed issuance of replacement warrants.

F1 · price: This portion of existing warrants held by Ms. Powers was extended in consideration for suspension of these warrants making them unexercisable until Nov. 1, 2020, and for suspension of other warrants held by Ms. Powers making those unexercisable until Nov. 1, 2020 as well. These extended warrants will have an exercise period of 2-1/2 years after the suspension period.

F1 · derivative.expiration_date: This portion of existing warrants held by Ms. Powers was extended in consideration for suspension of these warrants making them unexercisable until Nov. 1, 2020, and for suspension of other warrants held by Ms. Powers making those unexercisable until Nov. 1, 2020 as well. These extended warrants will have an exercise period of 2-1/2 years after the suspension period.

Read SEC document
April 30, 2020 Filed May 2, 2020 01:12 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 OtherWarrants · Derivative 29,411,760 $0.00 Strike: $0.22 $0.00
Disclosure

SEC source: 0001104659-20-055770 · tm2018427d1_4.xml · derivative · entry 1

Powers Linda F · CIK 0001289624 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 · 29,411,760 shares

Expires 2020-05-02

F2 · kind: Extension of an existing warrant is deemed to be a cancellation and re-issuance. H is the transaction code which covers cancellation of securities.

Read SEC document
January 27, 2020 Filed Jan 29, 2020 20:39 UTC Inmune Bio, Inc. INMB · Entity 7094 SaleCommon Stock 220,000 $4.60 $1,012,000.00
Disclosure

SEC source: 0001104659-20-008253 · tv537330_4.xml · nonDerivative · entry 1

Powers Linda F · CIK 0001289624 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,000

Read SEC document
December 28, 2018 Filed Jan 30, 2019 02:57 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 SaleClass D-2 Warrants · Derivative 402,073 $0.00 Strike: $0.30 $0.00
Disclosure

SEC source: 0001144204-19-003609 · tv511975_4.xml · derivative · entry 3

Powers Linda F · CIK 0001289624 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Sale by Toucan Capital Fund III, LP.

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 · 402,073 shares

Expires 2023-05-04

Read SEC document
December 28, 2018 Filed Jan 30, 2019 02:57 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 SaleRestricted Common Stock, par value $0.001 804,146 $0.17 $136,704.82
Disclosure

SEC source: 0001144204-19-003609 · tv511975_4.xml · nonDerivative · entry 1

Powers Linda F · CIK 0001289624 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Sale by Toucan Capital Fund III, LP.

Disclosed balance after: 0

F1 · shares: Toucan Capital Fund III, LP sold the 804,146 restricted shares of common stock that it owned, in preparation for the required dissolution due to the Toucan Fund reaching the end of its contractual term. The reporting person has management control as well as a partnership interest in the Toucan Fund.

Read SEC document
December 27, 2018 Filed Jan 30, 2019 02:57 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 SaleClass D-2 Warrants · Derivative 1,779,320 $0.00 Strike: $0.30 $0.00
Disclosure

SEC source: 0001144204-19-003609 · tv511975_4.xml · derivative · entry 4

Powers Linda F · CIK 0001289624 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 · 1,779,320 shares

Expires 2023-05-04

Read SEC document
December 27, 2018 Filed Jan 30, 2019 02:57 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 SaleRestricted Common Stock, par value $0.001 3,558,639 $0.17 $604,968.63
Disclosure

SEC source: 0001144204-19-003609 · tv511975_4.xml · nonDerivative · entry 2

Powers Linda F · CIK 0001289624 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,411,760

F2 · shares: The reporting party sold shares of restricted common stock.

Read SEC document
May 28, 2018 Filed May 31, 2018 01:59 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 GrantOptions to purchase Common Stock, par value $0.001 · Derivative 39,200,000 Not disclosed Strike: $0.23 Not disclosed
Disclosure

SEC source: 0001144204-18-031801 · tv495286_4.xml · derivative · entry 1

Powers Linda F · CIK 0001289624 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,200,000

Underlying: Common Stock, par value $0.001 · 39,200,000 shares

Expires 2028-05-28

F1 · shares: 29,400,000 of these 39,200,000 Options were previously reported on Form 8-K on January 16, 2018, following Board approval. Half of the Options are vested at the time of issuance and half will vest monthly over the course of 24 months from the date of Board approval, subject to acceleration in certain circumstances.

F2 · price: The exercise price of the Options is $0.23.

Read SEC document
March 19, 2018 Filed Mar 22, 2018 00:12 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 GrantConvertible Note · Derivative Not disclosed Not disclosed $400,000.00
Disclosure

SEC source: 0001144204-18-016240 · tv489185_form4.xml · derivative · entry 2

Powers Linda F · CIK 0001289624 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Class D-2 Warrants · 869,565 shares

Expires not disclosed

F1 · derivative.exercise_price: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · price: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · derivative.expiration_date: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · valueOwnedAfter: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

Read SEC document
March 19, 2018 Filed Mar 22, 2018 00:12 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 GrantConvertible Note · Derivative Not disclosed Not disclosed $400,000.00
Disclosure

SEC source: 0001144204-18-016240 · tv489185_form4.xml · derivative · entry 1

Powers Linda F · CIK 0001289624 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Series B Preferred Stock · 173,913 shares

Expires not disclosed

F1 · derivative.exercise_price: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · price: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · derivative.expiration_date: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · valueOwnedAfter: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

Read SEC document
March 19, 2018 Filed Mar 23, 2018 00:38 UTC Amendment NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 GrantClass D-2 Warrants · Derivative 869,565 Not disclosed Strike: $0.30 Not disclosed
Disclosure

SEC source: 0001144204-18-016504 · tv489355_4a.xml · derivative · entry 3

Powers Linda F · CIK 0001289624 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 869,565

Underlying: Common Stock · 869,565 shares

Expires not disclosed

F2 · security: As disclosed in the original filing and in footnote 1, certain Class D-2 Warrants were issued in connection with the notes issuance. This amendment is filed to further indicate the amount of such warrants.

F1 · price: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · derivative.expiration_date: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

Read SEC document
March 19, 2018 Filed Mar 23, 2018 00:38 UTC Amendment NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 GrantConvertible Note · Derivative Not disclosed Not disclosed $400,000.00
Disclosure

SEC source: 0001144204-18-016504 · tv489355_4a.xml · derivative · entry 2

Powers Linda F · CIK 0001289624 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Class D-2 Warrants · 869,565 shares

Expires not disclosed

F1 · derivative.exercise_price: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · price: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · derivative.expiration_date: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · derivative.underlying_shares: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · valueOwnedAfter: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

Read SEC document
March 19, 2018 Filed Mar 23, 2018 00:38 UTC Amendment NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 GrantConvertible Note · Derivative Not disclosed Not disclosed $400,000.00
Disclosure

SEC source: 0001144204-18-016504 · tv489355_4a.xml · derivative · entry 1

Powers Linda F · CIK 0001289624 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Series B Preferred Stock · 173,913 shares

Expires not disclosed

F1 · derivative.exercise_price: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · price: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · derivative.expiration_date: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · valueOwnedAfter: The reporting person made a new loan of $400,000 to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 10 Class D-2 Warrants, with the Warrants on half of the principal being due and issuable when the loan is provided, and the Warrants on half of the principal and all of the accrued interest being due on a proportional basis in the event of conversion of some or all of the Note. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

Read SEC document
March 14, 2018 Filed Mar 15, 2018 01:04 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 GrantClass D-2 Warrants · Derivative 8,695,652 Not disclosed Strike: $0.30 Not disclosed
Disclosure

SEC source: 0001144204-18-014763 · tv488530_4.xml · derivative · entry 3

Powers Linda F · CIK 0001289624 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,695,652

Underlying: Common Stock · 8,695,652 shares

Expires not disclosed

F1 · price: The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · derivative.expiration_date: The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

Read SEC document
March 14, 2018 Filed Mar 15, 2018 01:04 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 GrantConvertible Note · Derivative Not disclosed Not disclosed $4,000,000.00
Disclosure

SEC source: 0001144204-18-014763 · tv488530_4.xml · derivative · entry 2

Powers Linda F · CIK 0001289624 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Class D-2 Warrants · 8,695,652 shares

Expires not disclosed

F1 · derivative.exercise_price: The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · reported_value: The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · price: The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · derivative.expiration_date: The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · derivative.underlying_shares: The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · valueOwnedAfter: The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

Read SEC document
March 14, 2018 Filed Mar 15, 2018 01:04 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 GrantConvertible Note · Derivative Not disclosed Not disclosed $4,000,000.00
Disclosure

SEC source: 0001144204-18-014763 · tv488530_4.xml · derivative · entry 1

Powers Linda F · CIK 0001289624 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Series B Preferred Stock · 1,739,130 shares

Expires not disclosed

F1 · derivative.exercise_price: The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · reported_value: The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · price: The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · derivative.expiration_date: The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · derivative.underlying_shares: The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

F1 · valueOwnedAfter: The reporting person made a new loan of $4 million to the Company in the form of a note convertible into Series B Preferred Stock and Class D-2 Warrants. Approximately half of the Class D-2 Warrants are due and issuable when the loan is provided, and approximately half are due on a proportional basis in the event of conversion of some or all of the Note. The note bears interest at a rate of 10% per annum, and is repayable upon 15 days' notice from the holder (and no later than five years from the date of the Note). The conversion price is $2.30 for one share of Series B Preferred Stock and 5 Class D-2 Warrants. Each share of Series B Preferred Stock is convertible into 10 shares of common stock when such shares of common stock are authorized and available. The Class D-2 Warrants are not currently exercisable, will expire five years after they become exercisable and have an exercise price of $0.30.

Read SEC document
March 12, 2018 Filed Mar 15, 2018 01:04 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 OtherClass D-1 Warrants · Derivative 29,411,760 Not disclosed Strike: $0.22 Not disclosed
Disclosure

SEC source: 0001144204-18-014763 · tv488530_4.xml · derivative · entry 5

Powers Linda F · CIK 0001289624 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,411,760

Underlying: Common Stock · 29,411,760 shares

Expires not disclosed

F2 · kind: The reported transactions are exempt from Section 16(b) of the Exchange Act because the securities were received by the reporting person as payment of $5 million of debt previously contracted and owed by a third party to the reporting person (which was part of a larger debt previously contracted by the third party to the reporting person which was unpaid) as the third party was unable to make any repayment in cash.

F4 · price: A $5 million portion of a larger pre-existing debt owed by a third party to the reporting person was paid by assignment of this Series A Preferred Stock and Class D-1 Warrants to the reporting person as the third party was unable to make any repayment in cash.

F3 · derivative.exercise_date: Convertible and exercisable when the Company has sufficient shares of common stock authorized and available. The Class D-1 Warrants are not currently exercisable and will expire two years after they become exercisable.

F3 · derivative.expiration_date: Convertible and exercisable when the Company has sufficient shares of common stock authorized and available. The Class D-1 Warrants are not currently exercisable and will expire two years after they become exercisable.

Read SEC document
March 12, 2018 Filed Mar 15, 2018 01:04 UTC NORTHWEST BIOTHERAPEUTICS INC NWBO · Entity 5982 OtherSeries A Preferred Stock · Derivative 2,941,176 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0001144204-18-014763 · tv488530_4.xml · derivative · entry 4

Powers Linda F · CIK 0001289624 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,941,176

Underlying: Common Stock · 29,411,760 shares

Expires not disclosed

F2 · kind: The reported transactions are exempt from Section 16(b) of the Exchange Act because the securities were received by the reporting person as payment of $5 million of debt previously contracted and owed by a third party to the reporting person (which was part of a larger debt previously contracted by the third party to the reporting person which was unpaid) as the third party was unable to make any repayment in cash.

F4 · price: A $5 million portion of a larger pre-existing debt owed by a third party to the reporting person was paid by assignment of this Series A Preferred Stock and Class D-1 Warrants to the reporting person as the third party was unable to make any repayment in cash.

F3 · derivative.exercise_date: Convertible and exercisable when the Company has sufficient shares of common stock authorized and available. The Class D-1 Warrants are not currently exercisable and will expire two years after they become exercisable.

F3 · derivative.expiration_date: Convertible and exercisable when the Company has sufficient shares of common stock authorized and available. The Class D-1 Warrants are not currently exercisable and will expire two years after they become exercisable.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.